One major characteristic of the Eu2P programme is to provide a flexible and modular training in pharmacovigilance and pharmacoepidemiology to meet the on-the-job training needs.
All Eu2P trainings, the Master, Certificates and PhD are provided on the Eu2P e-learning platform. Live lectures and discussions are provided through web-based room conference.
Course examinations are also performed online through a web-based room where each student is supervised.
The fresher's week is a face-to-face session that happens at the beginning of each Master year to have the opportunity to meet all Eu2P trainees and main lecturers. Especially, the fresher's week allows introducing the trainees with the main lines of the programme and with the use of the e-learning platform. Each domain lecturers' team provides face-to-face lectures for half a day. The European location chosen for the fresher's week may be different each year.
Each enrolled Master trainee should participate to the fresher's week. If it is not possible, the trainee must follow all the fresher's week training contents on the e-learning platform.
Students: 1500 Euros; Professionals: 3000 Euros
Dr Antoine Pariente [module coordinator], Dr Pernelle Noize and Dr Francesco Salvo (from Université Bordeaux Segalen)
No work experience is required.
Fortunately enough I was able to find StudyPortals. Right from the start of the application to getting the confirmation of admission I was using StudyPortals.
Sign up for your personal newsletter and we will help you too.
We will send you all the information you need to find your dream study programme!
Together with the ISIC Association and British Council IELTS we offer you the chance to receive up to £10000 to expand your horizon and study abroad. We want to ultimately encourage you to study abroad in order to experience and explore new countries, cultures and languages.
Eu2P OFFERS COURSES IN PHARMACOVIGILANCE AND PHARMACOEPIDEMIOLOGY PROVIDED AND UPDATED BY A UNIQUE PARTNERSHIP OF SEVEN UNIVERSITIES, FIFTEEN PHARMACEUTICAL COMPANIES, THE FRENCH AND THE EUROPEAN MEDICINES AGENCIES.